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A B S T R A C T
Breast cancer is the most common neoplasm affecting women in the Western world. Many studies are still conducted
with the purpose of finding markers that could be used for early diagnosis and/or serve as possible reliable prognostic or
predictive parameters, but with conflicting results. At present, no markers are available for an early diagnosis of breast
cancer. For surveillance of patients with diagnosed breast cancer the most widely used serum markers are CA 15-3 and
CEA which, in combination with other clinical parameters, could have clinical significance. The most useful and clini-
cally important tissue-based markers in breast cancer are estrogen and progesterone receptors, used as a basis for hor-
monal therapy, and HER-2 receptors, essential in selecting patients for the treatment with Herceptin®. New or poten-
tially new markers for breast cancer include BRCA1 and BRCA2 genes for selecting patients at high risk of developing
hereditary breast cancer, as well as urokinase plasminogen activator and inhibitor for assessing prognosis in lymph
node-negative patients. Results of tumor and patient genetic analyses including their clinical evaluation will enable ap-
plication of more individualized and personalized approach in diagnosis and therapy of breast cancer patients.
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Introduction
Breast cancer is the most common type of non-skin
cancer and one of the most common cause of cancer
death for women in Western countries1. About 1.2 mil-
lion women will be diagnosed with breast cancer annu-
ally worldwide and about 411.000 will die from this
disease2. According to American Cancer Society 95% of
new breast cancer cases and 97% of breast cancer deaths
occur in women aged 40 and older3. Also, 50% of women
who developed breast cancer are age 61 or younger at the
time of diagnosis3. Lifetime risk of developing this malig-
nancy is 12.2% and a lifetime risk of death is 3.6%4,5.
Multiple factors are associated with an increase in breast
cancer risk, including genetic and familial predisposi-
tion, hormonal factors, diet, benign breast diseases and
environmental factors5,6. Over the past decade many im-
provements and new discoveries in the diagnosis, staging
and treatment of breast cancer patients, resulted in in-
creased survival of breast cancer patients.
Breast cancer is a heterogeneous and progressive dis-
ease and its early detection remains one of the most ur-
gent issues in cancer research. Because many breast can-
cers still escape early detection, identification of biologi-
cal tumor markers able to reveal early stage disease may
greatly reduce related mortality7. Furthermore, an effec-
tive follow-up is needed for all treated patients who may
develop progression recurrence of the disease during
their life8.
Potential use of markers in breast cancer include
early diagnosis of the disease, determining prognosis,
predicting response or resistance to specific therapies,
surveillance after primary surgery and monitoring ther-
241
Received for publication October 11, 2010
apy in patients with advanced disease9. Because tumor
markers have weak sensitivity and specificity, especially
in patients with early stage disease, their prognostic rele-
vance and clinical usefulness is still controversial. So far,
the main prognostic factors for both disease free survival
(DFS) and overall survival (OS) in breast cancer patients
are nodal involvement, tumor size, lymphatic and vascu-
lar invasion, histological grade, nuclear grade and sex
steroid receptors5,6.
Serum Tumor Markers
Serum tumor markers (STM) are soluble molecules in
blood, usually glycoproteins, detected by monoclonal an-
tibodies. They are released into the blood by tumor cells
or by other cells in response to tumor cells. STM are the
most extensively used in clinical practice because they
reflect the dynamic evolution of the disease and their lev-
els can be easily repeated when required9. STM are
widely examined for detection of malignancies, for as-
sessing outcome or predicting recurrence and for moni-
toring the response to anticancer therapies9.
Some of STM commonly used in breast cancer pa-
tients include certain members of MUC-1 family of mu-
cin glycoproteins, such as CA 15-3 (PEM – polymorphic
epithelial mucin; or EMA – epithelial membrane antigen;
or episalin), CA 27.29, MCA and CA 549; carcinoem-
bryonic antigen (CEA), certain oncoproteins (shed form
of HER-2) and cytokeratins (TPA, TPS). Members of the
MUC-1 family are most widely used STM in breast can-
cer, and among them CA 15-3 is generally regarded as the
most specific and sensitive10. Because of their similar di-
agnostic sensitivities and specificities, the use of more
then one MUC-1 marker is unlikely to confer any advan-
tage11. CA 15-3 and CEA are currently the most often used
tumor markers for breast cancer in clinical practice12.
MUC-1
MUC-1 is a high weight glycoprotein encoded by the
MUC-1 gene and well expressed on the apical surface of
most polarized epithelial cells of different organs includ-
ing breast, stomach, pancreas, bladder and respiratory
tract13. In normal breast tissue MUC-1 is expressed in
the ducts and acini from where it is released into the
milk in soluble form or bound to milk fat globules. Neo-
plastic transformation is associated with disruption of
normal cell polarization and tissue architecture leading
to MUC-1 shedding in the bloodstream where it can be
measured by means of immunoassays. MUC-1 is biologi-
cally significant because it can activate membrane recep-
tors for growth factors, reduce E-cadherin-mediated cell
adhesion thereby promoting cell migration, and reduce
the cellular apoptotic response to oxidative stress14–17.
Members of MUC-1 family are detected by mono-
clonal antibodies that bind to epitopes on the MUC-1
molecule. Reactive with different epitopes monoclonal
antibodies identified several serum antigens, such as
cancer antigen CA 15-3, mucin-like carcinoma associated
mucin (MCA), CA 549, CA 27.29, breast cancer mucin
(BCM), EMCA, M26 and M2918. Among these antigens,
the most widely used is CA 15-3, and more recently CA
27.29. According some authors, CA 27.29 is similar to CA
15-3 for metastatic breast cancer detection and monitor-
ing, but more sensitive18.
Carcinoembryonic antigen (CEA)
One of the first studied and used markers was car-
cinoembryonic antigen (CEA), an oncofetal glycoprotein
that is expressed in normal mucosal cells and over-
expressed by adenocarcinomas, primarily of the colon,
rectum, breast, pancreas, and lung. Immunobiological
and biochemical studies have revealed that CEA consists
of a large family of at least 30 closely related cell surface
glycoproteins encoded by about ten genes located on
chromosome 1919,20. The domain structure of CEA pro-
teins and the gamma heavy chain of the immunoglobulin
IgG are very similar, suggesting that CEA is part of the
immunoglobulin gene »superfamily«. This finding indi-
cates that CEA proteins may be involved in the inter-
cellular or cellular-matrix recognition mechanisms.
Cytokeratins
Several widely used tumor markers such as tissue
polypeptide antigen (TPA), tissue polypeptide specific
antigen (TPS) and Cyfra 21.1 are molecules that struc-
turally belong to the family of cytokeratins (CKs). CKs
constitute one of the seven classes of intermediate fila-
ments that, together with microtubules and actin micro-
filaments, make up the cytoskeleton of most eukaryotic
cells21,22. Human CKs comprise 20 related polypeptides
(CKs 1–20) which, on the basis of sequence homologies,
can be separated into two subfamilies. CKs 9–20 are the
more acidic, type-I CKs, while CKs 1–8 form the neu-
tral/basic type II group of proteins. In epithelial cells
from many tissues, the combinations CK8/CK18 and
CK8/CK19 are very often expressed. These pairs of CKs
are also very commonly found in the vast majority of epi-
thelial breast carcinomas23–25. Different tumor marker
assays measuring CK8, CK18 and CK19 fragments have
been developed, the most widely used being TPA, TPS
and Cyfra 21.1. The TPA test recognizes all three CKs
(CK8, CK18 and CK19), TPS measures CK8 and CK18,
and Cyfra 21.1 detects CK8 and CK19.
Assessment of serum tumor markers’ clinical
use
Screening and early diagnosis
Due to low sensitivity of available tumor markers in
early stage disease, only mammographic screening may
result in a justified suspicion of breast cancer26. Various
studies have demonstrated that the diagnostic sensitivity
of the CA 15-3 test is about 10–15%, 20–25% and 30–45%
in patients with stage I, stage II and stage III disease,
respectively12. However, low levels of tumor markers in
patients with suspected breast cancer does not exclude
the presence of malignancy11.
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The sensitivity and specificity of tumor markers is
significantly higher in patients with advanced disease
and it is related to the site of recurrence11. Simultaneous
use of CA 15-3 and CEA markers allows early diagnosis
of metastases (mainly in bone and liver) in up to 60–80%
of patients with breast cancer11. By using combinations
of CA 15-3, CEA and cytokeratins, it was possible to in-
crease the sensitivity to at least 90% in patients with dis-
tant metastases11. Recent reports indicate that CA 27.29
is a more sensitive test than CA 15-327. The CA 27.29
level is elevated in approximately one third of women
with early-stage breast cancer (stage I or II) and in two
thirds of women with late-stage disease (stage III or
IV)27. However, CA 27.29 lacks predictive value in the
earliest stages of breast cancer and thus has no role in
screening or diagnosing the malignancy.
Prognosis and surveillance
Various studies confirmed that preoperative elevated
levels of either CA 15-3 or CEA are indicators of adverse
effects in breast cancer patients, and therefore can be
used as prognostic factors for both disease-free survival
(DFS) and overall survival (OS)28,29. Together with CA
15.3 and CEA, serum HER-2 concentrations with tissue
overexpression showed to be useful tool in the prognostic
evaluation of patients with primary breast cancer30. The-
re are still conflicting data for CA 15-3 marker but so far,
it appeared to have the strongest prognostic value among
STM. Elevated CA 15-3 level can be a marker of en-
hanced risk of recurrence and mortality in both early-
and late stage breast cancer12. Indeed, in some studies
the prognostic impact of CA 15-3 was independent of tu-
mor size and axillary nodal status31,32. Significantly, in
two reports31,32 CA 15-3 was found to be prognostic in
lymph node–negative breast cancer patients. In another
study however, CA 15-3 was not prognostic in patients
free of axillary nodal metastases33. Although some pa-
tients with high levels of CA15-3 demonstrated shorter
DFS and OS, the role of this marker as independent
prognostic factors has not been proven12.
It has been shown that high preoperative concentra-
tions of CEA can be associated with poor prognosis in
breast cancer29,33. Furthermore, in one large study (n
=1046) patients with a decrease of 33% between pre- and
postoperative concentrations were found to have a worse
outcome than those with a lesser decrease29. In multi-
variate analysis, this decrease in CEA predicted outcome
independent of tumor size, lymph node status, and pro-
gesterone receptors. Nevertheless, elevated CEA levels
can suggest worse, unaffected or even better prognosis,
therefore CEA determination is of limited clinical utility.
Therapy monitoring
Potential clinical application of STM in monitoring
breast cancer patients response to therapy has been sub-
ject of numerous studies, but with controversial results7.
For patients with metastatic breast cancer, some correla-
tion to response to therapy was reported for CA 15-3,
MCA, CA 549 and for TPS, but CA 15-3 shown to be more
effective and generally superior to CEA and other STM7,12.
According to meta-analysis, in a majority of patients
treated for advanced breast cancer, decreasing level of
CA 15-3 correlated with the response to therapy, while
patients with cancer progression had increasing level of
this marker7. CA 15-3 was shown to be useful in the mon-
itoring of response to endocrine therapy and cytotoxic
therapy12.
For patients with advanced breast cancer Interna-
tional Unit against Cancer (UICC) criteria, referring to
clinical characteristics of tumor burden, have been tradi-
tionally used for assessing response to therapy34. Combi-
nation of CA 15-3, CEA and erythrocyte sedimentation
rate (ESR) has been used to obtain biochemical score in-
dex that correlated with UICC criteria used for therapy
monitoring11. Changes in serial measurements of a MUC-
-1 may be helpful in assessing the course of the disease
and some authors suggested a major role of CA 15-3 in
monitoring the response to chemotherapy7. However, not
all international guidelines recommend use of CA 15-3 in
therapy monitoring, since up to one third of advanced
breast cancer patients did not show any changes of tu-
mor marker at disease progression7. In contrast to the
American Society of Clinical Oncology (ASCO) Panel, both
the National Academy of Clinical Biochemistry (NACB)
and European Group of Tumor Markers (EGTM) Panels
recommended use of CA 15-3 for monitoring therapy in
patients with advanced breast cancer11,35.
Emerging data suggest that determination of serum
HER-2 may be of use in patients undergoing treatment
with trastuzumab-based therapy. Preliminary findings
suggest that high serum HER-2 concentrations are asso-
ciated with both poor response to endocrine therapy and
cyclophosphamide-methotrexate-5-fluorouracil-based
chemotherapy but can predict an improved response to a
combination of trastuzumab (Herceptin®) and chemo-
therapy36. These early findings, however, require valida-
tion in a large prospective trial before serum HER-2 level
can be recommended for monitoring of trastuzumab-
-based treatment in patients with advanced breast cancer.
Tissue Tumor Markers
Tissue tumor markers can be identified with different
methods in tumor tissue and some of them can have
prognostic and predictive value. Tissue markers are tis-
sue antigens such as proteins or hormone receptors de-
tected by antibodies that bind to tissue antigens in fresh,
frozen or formalin-fixed, paraffin-embedded tissue sec-
tions. Tissue based markers are primarily measured in
order to determine prognosis and predict response to
therapy11. At present, steroid receptors, estrogen (ER)
and progesterone (PR) receptors, as well as HER-2 (also
known as c-erbB-2 or neu) are markers accepted in stan-
dard clinical practice. They are not useful in early diag-
nosis, as they may be present in both benign and malig-
nant tissue, but they have prognostic and predictive
value in primary and in metastatic breast cancer. Clinical
decisions regarding hormonal or immunotherapy in breast
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cancer patients is based on obligatory determination of
steroid and HER-2 receptors in all breast tumors.
Urokinase plasminogen activator (uPA) and plasmi-
nogen activator inhibitor 1 (PAI-1) represents potential
markers for determining prognosis in lymph node-nega-
tive breast cancer patients11.
Breast cancer, as heterogeneous disease, can be classi-
fied using gene microarray analyses into four different
subtypes, which also include ER, PR and HER-2 receptor
status. This classification includes: basal-like subtypes
(which are mostly triple negative – ER negative, PR neg-
ative and HER2 negative), luminal A (ER positive and
low grade), luminal B (ER positive and high grade) and
HER2 positive. It has been shown that these breast can-
cer subtypes have different prognostic and possible ther-
apeutic implications37.
Estrogene and progesterone receptors
The ER has a central role in the development of
breast cancer38. According to the College of American Pa-
thologists both the estrogene and the progesterone re-
ceptor constitute a first category of prognostic factors in
breast cancer39. ER and PR are transcriptional factors
which mediate the actions of estrogens and progesterone,
respectively40,41. Both receptors are now known to exist
in two different isoforms. For ER, these forms are known
as ER-a and ER-ß42 and for PR the two forms are known
as PRA and PRB43. It appears that only ER-a is critical
for mammary gland development and tumorigenesis. Ex-
isting assays for PR do not discriminate between the two
forms.
Hormone status is considered a very strong predictor
of response to hormonal therapy in breast cancer pa-
tients. In both early and advanced disease hormone re-
ceptor-positive patients have a significantly greater pro-
bability of responding to hormone therapy than patients
lacking receptors44. Therefore, hormone receptor deter-
mination is obligatory in all breast cancer patients and
methodology of steroid receptor determination is recom-
mended by ASCO guidelines. Three well-established as-
says exist for measuring hormone receptors, namely ligand
binding, ELISA and immunohistochemistry11. Positive
hormone receptors represent basis for different hormo-
nal therapy appliance in early stage, as well as advanced
breast cancer disease.
Information on receptor status may also be of prog-
nostic value. Generally, for the first 4–5 years after diag-
nosis, ER-positive patients have a better outcome than
ER-negative patients45. However, after this period, the
favorable prognostic impact of ER is lost. Approximately
30–40% of ER positive patients do not respond to endo-
crine therapy, while some ER negative patients are res-
ponsive7. A further limitation of ER as a prognostic fac-
tor is that it is of little value in lymph node negative
patients45. However, hormone receptors may be com-
bined with classic clinical prognostic factors in determin-
ing outcome in breast cancer patients11.
HER-2 receptor
HER-2, a proto-oncogene, is the most commonly am-
plified oncogene in human breast cancer46. HER-2 en-
codes a transmembrane protein belonging to the epider-
mal growth factor receptor family47. HER-2 gene is either
amplified or overexpressed in 15–30% of invasive breast
cancers11. Determination of HER-2 status is obligatory
for all breast cancer patients. Methodology for identify-
ing HER-2 status provided by ASCO recommendations
includes immunohistochemistry, which measures over-
-expression of the HER-2 full-length oncoprotein (p185);
fluorescent in situ hybridization (FISH), which measures
the number of HER-2/neu gene copies48. A third tissue
method is chromogenic in situ hybridization (CISH)49.
Tumors with HER-2 overexpression tend to be higher
grade and hormone receptor negative, resulting in a
worse prognosis45. Studies support that HER-2 over-
expression is a poor prognostic factor, although its mag-
nitude appears weak50.
All patients with positive HER-2 receptors have to be
treated by immunotherapy with Herceptin® (trastuzu-
mab). To select breast cancer for the treatment with
Herceptin® (trastuzumab), determination of HER-2 tu-
mor expression is obligatory by all patients. Herceptin®
is a humanized monoclonal antibody that binds with
high affinity to the extracellular domain of HER-2, the-
reby blocking its role in signal transduction. Herceptin®
is now widely used for the treatment of HER-2-positive
tumor patients with advanced breast cancer, as well as
for adjuvant treatment of HER-2 positive patients with
early breast cancer. However, some HER-2 positive tu-
mors have a primary or acquired resistance to trastu-
zumab. Patients with tumors that overexpress HER-2
appear to have relative resistance to some chemotherapy
regimens, such as cyclophosphamide, methotrexate and
5-fluorouracil (CMF), but not to others, such as an-
thracycline-containing regimens51. The level of available
evidence does not support using HER-2 status to predict
response to chemotherapy50.
Most published reports on axillary node-positive breast
cancer patients conclude that either HER-2 gene amplifi-
cation or overexpression correlates with an adverse out-
come in patients with breast cancer52. HER-2 should not
be used alone for determining outcome in patients with
breast cancer.
uPA and PAI-1
Urokinase plasminogen activator (uPA) and its inhib-
itor PA1-1 have been investigated as potential prognostic
markers in breast cancer patients. uPA is a serine prote-
ase implicated in cancer growth, invasion and meta-
stasis53. PAI-1 is an endogenous inhibitor of uPA but par-
adoxically is also involved in tumor progression. Multiple
single institutional studies have shown that both uPA
and PAI-1 are potent and independent prognostic factors
in breast cancer. This prognostic impact of uPA and
PAI-1 has been shown in both lymph node negative and
lymph node-positive breast cancer patients53. Patients
with low levels of both these proteins are at a relatively
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low risk of developing recurrent or metastatic disease
and, consequently, may be able to avoid the toxic side ef-
fects and costs of adjuvant chemotherapy but further in-
vestigation is needed11.
Other tissue-based markers
Potential biological breast cancer markers are subject
of numerous investigations. One of the most common ge-
netic alterations found in breast cancer is mutation of
gene p53, which has a pivotal role in the entire mecha-
nism of apoptosis54. Although some studies showed in-
triguing results, the update of ASCO guidelines con-
firmed the lack of utility of p53 in management of breast
cancer55. Proliferation markers such as nucleic protein
Ki-67 is also used as a marker for breast cancer, with
maximal expression during S and M phase of cell cycle.
Cathepsin D, a glycoprotein with proteolytic activity, as-
sociated with tumor growth and progression, has been
found elevated in up to 69% of patients with metastatic
breast cancer55. Based on available evidence, a routine
determinations of cathepsin D, or other breast cancer tis-
sue markers such as cathepsin B, TGF-a, e-cadherin,
nm23, or c-myc, cannot be recommended at present.
Gene expression profiling
Instead of measuring individual markers, the use of
DNA microarray or gene expression profiling is a popular
current research approach for determing prognosis or
predict response to therapy. Although results are promis-
ing, this technology is technically demanding, time-con-
suming, expensive and requires further clinical evalua-
tion.
Multigene expression: oncotype DX™
Oncotype DXTM, created by Genomic Health, is a
more recent example of new tumor marker development
that has been included in the 2007 American Society of
Clinical Oncology (ASCO) Clinical Guidelines on Use of
Tumor Markers in Breast Cancer55. It represents a diag-
nostic test that quantifies the likelihood of disease recur-
rence in women with early-stage breast cancer and as-
sesses the likely benefit from certain types of chemother-
apy. The investigators specifically developed the test to
determine prognosis in ER-positive, lymph node-nega-
tive patients who were treated with tamoxifen56.
Oncotype DXTM, also known as a genomic assay, is a
noninvasive test performed on a small amount of the tis-
sue that analyses the activation of a groups of genes from
which can be established how a cancer is likely to grow
and respond to treatment. During the test a panel of 21
genes is analyzed within a tumor with the use of RT-
-PCR, a highly reproducible laboratory assay that deter-
mines the expression of these genes. Based on this analy-
sis Oncotype DXTM assigns the breast cancer a Recur-
rence Score (RS) that represents a number between 0
and 100 that corresponds to a specific likelihood of breast
cancer recurrence within 10 years of the initial diagnosis.
The lower your score the less likely the cancer is to recur
and vice-versa.
Oncotype DXTM is both a prognostic test, since it pro-
vides more information about how likely (or unlikely) the
breast cancer is to come back, and a predictive test, since
it predicts the likelihood of benefit from chemotherapy
treatment. 2007 ASCO Guidelines recommend the use of
Oncotype DXTM to predict the risk of recurrence in pa-
tients treated with tamoxifen and to identify patients
who are predicted to obtain the most therapeutic benefit
from adjuvant tamoxifen and may not require adjuvant
chemotherapy55. Patients with high recurrence scores
(RSs) appear to achieve relatively more benefit from
adjuvant chemotherapy than from tamoxifen.
Besides Oncotype DXTM, there are three commercially
available multigene assays to determine clinical out-
comes in primary breast cancer: MammaPrint®, Map-
Quant DxTM and THEROS Breast Cancer IndexTM57.
Among them, clinical use of Oncotype DXTM (21-gene RS
assay) and MammaPrint® (70-gene assay) increased in
recent years57. Nevertheless, several limitations and ca-
veats exist regarding the prediction utility of multigene
assays and further clinical evaluation is needed57.
Genetic Tumor Markers
BRCA1 and BRCA2
Genetic tumor markers BRCA1 and BRCA2 are a can-
cer predisposing human genes used for risk assessment
in individuals with a familial history of breast cancer.
They belong to a class of genes known as tumor sup-
pressors which maintain genomic integrity to prevent
dangerous genetic changes in normal cells. Inherited mu-
tations can identify individuals who are at an increased
risk for the development of breast and ovarian cancers,
as well as other cancers. Although BRCA1 and BRCA2
mutations are strong predictors of breast cancer develop-
ment, they occur in less than one out of 1000 women in
breast cancer7. About 50 to 60% of women with heredi-
tary mutation in BRCA1 and BRCA2 genes will develop
breast cancer till the age of 70. Also, they can have en-
hanced risk of developing ovarian cancer7.
The BRCA1 gene is located on the long arm of chro-
mosome 17 (17q21) and has 3.4 kb with 24 exons. It en-
codes a 190 kDa protein containing 1863 amino acids in-
volved in regulating transcription, inhibiting cellular
proliferation and repairing DNA58,59. According to the
biochemical analogy protein is homologue to granin pro-
tein family that is involved in suppression of epithelium
proliferation of estrogen dependant tissue. Over 1000
mutations, mostly nonsence or frameshift, in the BRCA1
gene have now been described60. BRCA2, larger gene
than BRCA1, has 2.5 kb with 27 exons. It codes for a 380
kDa protein of 3418 amino acids with similar functions
as BRCA1 protein, homologue to granin family61. The
BRCA2 gene is located on chromosome 13q1261.
Studies showed that women who carry either a BRCA1
or BRCA2 gene mutations have 82% of lifetime risk of de-
veloping breast cancer62. BRCA1 mutation carriers have
about 60% lifetime risk of ovarian cancer while BRCA2
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mutation carriers have about 27%. Males possessing a
mutation in BRCA2 gene have a 5% risk of developing
breast cancer. BRCA1 mutation on the other hand, does
not appear to increase the risk of male breast cancer62.
Genetic testing for BRCA1 or BRCA2 mutations in
patients with a familial history of breast cancer may pro-
vide, along with other clinico-pathohistological parameters,
information for patient-specific diagnostic and treatment
regimens.
Recently, a lot of emphasis has been put on newly de-
veloped molecular approaches, genomics and especially
proteomics, thanks to whom changes in molecular mech-
anisms and signaling pathways underlying breast cancer
have been enlightened. Certain key genes including HOXA1,
c-Myc, cyclin D1, and Bcl-2 that express oncolytic activity
when altered, have been identified63. Also, highly ex-
pressed BRMS1 gene can influence MHC genes that are
directly involved in secretion, cell adhesion, prolifera-
tion, localization, and metabolism63.
Conclusion
In order to obtain more successful diagnosis and ther-
apy of breast cancer, finding markers for early diagnosis,
reliable prognosis and therapy prediction could be of cru-
cial importance. The clinical usefulness of tumor mark-
ers in breast cancer is still an area of investigation, with
often controversial results. Due to low specificity and
sensitivity, no markers are available at present for early
diagnosis of breast cancer. For patients with diagnosed
breast cancer, the most widely used serum markers are
CA 15-3 and CEA, which in combination with other clini-
cal parameters could have significance in patients’ sur-
veillance. Serial determination of these markers may be
useful in routine therapy monitoring and for early detec-
tion of recurrence and progression during follow-up. The
most useful and clinically important tissue-based mark-
ers in breast cancer are steroid receptors (estrogen and
progesterone receptors) and HER-2 protooncogene re-
ceptor. Steroid receptor status is used to predict response
to hormonal therapy, which represents an important
form of treatment for patients with steroid receptors pos-
itive breast cancer. HER-2 protooncogene receptor has
predictive value for response to immunotherapy and all
patients with positive HER-2 receptors have to be trea-
ted with Herceptin® (trastuzumab), in both early and
advanced breast cancer disease. Determination of steroid
receptors and HER-2 receptor status is obligatory for all
breast cancer patients. Genetic testing for BRCA1 or
BRCA2 mutations in patients with a familial history of
breast cancer may provide, along with other clinico-
-pathohistological parameters, information for patient-
-specific diagnostic and treatment regimens. uPA and
PAI-1 are recently validated as prognostic factors for
lymph node-negative breast cancer patients and thus
may be used in selecting those node-negative patients
who may not need to receive adjuvant chemotherapy. Ge-
netic testing for BRCA1 or BRCA2 mutations in patients
with a familial history of breast cancer may provide,
along with other clinico-pathohistological parameters,
information for patient-specific diagnostic and treatment
regimens. Results of tumor and patient genetic analyses,
including their clinical evaluation, will enable applica-
tion of more individualized and personalized approach in
diagnosis and therapy of breast cancer patients.
Human blood and tissue represent rich sources of
biomarkers; therefore additional studies have to be con-
ducted to discover new markers with the ultimate goal of
exploiting their use in the screening and early diagnosis
of primary breast cancer. The use of selected marker in
breast cancer as prognostic or predictive parameters
should lead to a better and a more cost effective manage-
ment of these patients. Hopefully, this will result in en-
hanced survival and better quality of life of breast cancer
patients.
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TUMORSKI MARKERI RAKA DOJKE – PROCJENA NJIHOVE KLINI^KE PRIMJENE
S A @ E T A K
Rak dojke je naj~e{}a maligna bolest `ena u zapadnom svijetu. Mnoga istra`ivanja se jo{ uvijek provode u cilju
pronala`enja markera koji bi mogli koristiti za ranu dijagnostiku, te slu`iti kao mogu}i pouzdani prognosti~ki ili pre-
diktivni pokazatelji, me|utim, rezultati tih istra`ivanja su kontradiktorni. Trenutno ne postoji marker za rano ot-
krivanje raka dojke. Za pra}enje bolesnica s dijagnosticiranim rakom dojke, naj~e{}e kori{teni serumski markeri su CA
15-3 i CEA, koji u kombinaciji s drugim klini~kim pokazateljima mogu imati klini~ku primjenu. Od tkivnih markera,
najkorisniji i klini~ki najzna~ajniji markeri su estrogenski i progesteronski receptori, koji se koriste kao osnova hor-
monske terapije, te HER-2 receptori, klju~ni u odabiru bolesnika za lije~enje Herceptinom®. Novi, ili potencijalno novi
markeri raka dojke uklju~uju gene BRCA1 i BRCA2, koji se koriste u odabiru bolesnica s visokim rizikom razvoja
nasljednog raka dojke, te urokinaza plazminogen aktivator i inhibitor, kori{teni za procjenu prognoze u bolesnika s
negativnim limfnim ~vorovima. Rezultati geneti~kih analiza tumora i bolesnica, uz njihovo klini~ko vrednovanje, omo-
gu}it }e individualizirani i personalizirani pristup dijagnostici i terapiji bolesnica s rakom dojke.
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